BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 16428939)

  • 1. Comparative anti-tumor efficacy of two orally administered platinum(IV) drugs in nude mice bearing human tumor xenografts.
    Sova P; Mistr A; Kroutil A; Zak F; Pouckova P; Zadinova M
    Anticancer Drugs; 2006 Feb; 17(2):201-6. PubMed ID: 16428939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New platinum(IV) complex with adamantylamine ligand as a promising anti-cancer drug: comparison of in vitro cytotoxic potential towards A2780/cisR cisplatin-resistant cell line within homologous series of platinum(IV) complexes.
    Turánek J; Kasná A; Záluská D; Neca J; Kvardová V; Knötigová P; Horváth V; SIndlerová L; Kozubík A; Sova P; Kroutil A; Zák F; Mistr A
    Anticancer Drugs; 2004 Jun; 15(5):537-43. PubMed ID: 15166629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical anti-tumor activity of a new oral platinum(IV) drug LA-12.
    Sova P; Mistr A; Kroutil A; Zak F; Pouckova P; Zadinova M
    Anticancer Drugs; 2005 Jul; 16(6):653-7. PubMed ID: 15930894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro.
    Kozubík A; Horváth V; Svihálková-Sindlerová L; Soucek K; Hofmanová J; Sova P; Kroutil A; Zák F; Mistr A; Turánek J
    Biochem Pharmacol; 2005 Feb; 69(3):373-83. PubMed ID: 15652229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
    Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo model development of cisplatin-resistant and -sensitive A2780 human ovarian carcinomas.
    Rose WC; Basler GA
    In Vivo; 1990; 4(6):391-6. PubMed ID: 2103379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical antitumor activity of the oral platinum analog satraplatin.
    Wosikowski K; Lamphere L; Unteregger G; Jung V; Kaplan F; Xu JP; Rattel B; Caligiuri M
    Cancer Chemother Pharmacol; 2007 Sep; 60(4):589-600. PubMed ID: 17541592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platinum(IV) complex with adamantylamine overcomes intrinsic resistance to cisplatin in ovarian cancer cells.
    Horváth V; Blanárová O; Svihálková-Sindlerová L; Soucek K; Hofmanová J; Sova P; Kroutil A; Fedorocko P; Kozubík A
    Gynecol Oncol; 2006 Jul; 102(1):32-40. PubMed ID: 16364413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retention of activity by the new generation platinum agent AMD0473 in four human tumour cell lines possessing acquired resistance to oxaliplatin.
    Sharp SY; O'Neill CF; Rogers P; Boxall FE; Kelland LR
    Eur J Cancer; 2002 Nov; 38(17):2309-15. PubMed ID: 12441268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis of a monofunctional platinum compound and its activity alone and in combination with phytochemicals in ovarian tumor models.
    Arzuman L; Beale P; Yu JQ; Proschogo N; Huq F
    Anticancer Res; 2014 Dec; 34(12):7077-90. PubMed ID: 25503135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different cell cycle modulation following treatment of human ovarian carcinoma cells with a new platinum(IV) complex vs cisplatin.
    Horváth V; Soucek K; Svihálková-Sindlerová L; Vondrácek J; Blanárová O; Hofmanová J; Sova P; Kozubík A
    Invest New Drugs; 2007 Oct; 25(5):435-43. PubMed ID: 17520175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative activity and distribution studies of five platinum analogues in nude mice bearing human ovarian carcinoma xenografts.
    Boven E; van der Vijgh WJ; Nauta MM; Schlüper HM; Pinedo HM
    Cancer Res; 1985 Jan; 45(1):86-90. PubMed ID: 4038381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
    Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
    Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis of trans-bis-(2-hydroxypyridine)dichloroplatinum(II) and its activity in human ovarian tumour models.
    Deqnah N; Yu JQ; Beale P; Fisher K; Huq F
    Anticancer Res; 2012 Jan; 32(1):135-40. PubMed ID: 22213298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cycloplatam: a novel platinum compound exhibiting a different spectrum of anti-tumour activity to cisplatin.
    Drees M; Dengler WM; Hendriks HR; Kelland LR; Fiebig HH
    Eur J Cancer; 1995; 31A(3):356-61. PubMed ID: 7786602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platinum(IV) complex LA-12 exerts higher ability than cisplatin to enhance TRAIL-induced cancer cell apoptosis via stimulation of mitochondrial pathway.
    Jelínková I; Šafaříková B; Vondálová Blanářová O; Skender B; Hofmanová J; Sova P; Moyer MP; Kozubík A; Kolář Z; Ehrmann J; Hyršlová Vaculová A
    Biochem Pharmacol; 2014 Dec; 92(3):415-24. PubMed ID: 25285768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative study of pharmacokinetics, urinary excretion and tissue distribution of platinum in rats following a single-dose oral administration of two platinum(IV) complexes LA-12 (OC-6-43)-bis(acetato)(1-adamantylamine)amminedichloroplatinum(IV) and satraplatin (OC-6-43)-bis(acetato)amminedichloro(cyclohexylamine)platinum(IV).
    Sova P; Mistr A; Kroutil A; Semerád M; Chlubnová H; Hrusková V; Chládková J; Chládek J
    Cancer Chemother Pharmacol; 2011 Jun; 67(6):1247-56. PubMed ID: 20697713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and activity of a trinuclear platinum complex: [{trans-PtCl(NH3)2}2mu-{trans-Pt(3-hydroxypyridine)2(H2N(CH2)6NH2)2}]Cl4 in ovarian cancer cell lines.
    Tayyem H; Huq F; Yu JQ; Beale P; Fisher K
    ChemMedChem; 2008 Jan; 3(1):145-51. PubMed ID: 17963210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and antitumour activity of a new trinuclear platinum compound [{cis-PtCl(NH3)2μ {trans-Pt(3-hydroxypyridine)2H2N(CH2)5NH2)2}] Cl4 in human ovarian cancer cells.
    Hamad SA; Beale P; Yu JQ; Huq F
    Anticancer Res; 2014 Apr; 34(4):1923-9. PubMed ID: 24692727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secondary screening of platinum compounds in human ovarian cancer xenografts in nude mice.
    Boven E; Nauta MM; Schluper HM; Elferink F; van der Vijgh WJ; Pinedo HM
    Eur J Cancer Clin Oncol; 1985 Oct; 21(10):1253-60. PubMed ID: 4076289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.